- Home
- TIL vs CNTX Comparison
TIL vs CNTX Comparison
Compare TIL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | CNTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 51.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TIL | CNTX |
|---|---|---|
| Price | $7.78 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $125.00 | $6.60 |
| AVG Volume (30 Days) | 15.8K | ★ 4.2M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.06 | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $0.55 |
| 52 Week High | $33.83 | $3.62 |
Technical Indicators
Market Signals| Indicator | TIL | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 27.73 |
| Support Level | $7.51 | $0.55 |
| Resistance Level | $8.25 | $2.54 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 60.27 | 41.82 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.